Skip to main content
. 2023 Aug 5;12(1):2243169. doi: 10.1080/2162402X.2023.2243169

Figure 3.

Figure 3.

Proportion of immunoscore-IC-High and Immunoscore-IC-Low (left) in metastatic colorectal cancer patients from AtezoTribe trial. Proportion (%) of patients according to MMR, TMB and immunoscore-IC status. Proportion (%) of patients relapsing in the treatment arm for each category (right).